Literature DB >> 6313600

The biochemistry and mechanism of action of acyclovir.

G B Elion.   

Abstract

Acyclovir, 9-(2-hydroxyethoxymethyl)guanine, is an acyclic nucleoside analogue which has a high activity and selectivity for herpes viruses, particularly herpes simplex viruses types 1 and 2 and varicella zoster virus. This selectivity is due to the initial activation of the drug by phosphorylation by a herpes virus-specified thymidine kinase. Normal cellular enzymes do not phosphorylate acyclovir to any significant degree. Acyclovir monophosphate is subsequently converted to a triphosphate which is a more potent inhibitor of herpes virus DNA polymerases than of cellular DNA polymerases. The relationship between the amount of acyclovir triphosphate formed and its inhibition constant (Ki) for the particular viral or cellular DNA polymerase is predictive of the inhibitory activity of acyclovir on DNA replication.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313600     DOI: 10.1093/jac/12.suppl_b.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  41 in total

1.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

2.  Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide.

Authors:  P R Kinchington; G Inchauspe; J H Subak-Sharpe; F Robey; J Hay; W T Ruyechan
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Posttranscriptional regulation of a class of human cytomegalovirus phosphoproteins encoded by an early transcription unit.

Authors:  D A Wright; D H Spector
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

Review 4.  Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer.

Authors:  Susanne M Bailer; Christina Funk; André Riedl; Zsolt Ruzsics
Journal:  Virus Genes       Date:  2017-06-20       Impact factor: 2.332

5.  Identification and characterization of a major early cytomegalovirus DNA-binding protein.

Authors:  D G Anders; A Irmiere; W Gibson
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

6.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.

Authors:  Utthara Nayar; Jouliana Sadek; Jonathan Reichel; Denise Hernandez-Hopkins; Gunkut Akar; Peter J Barelli; Michelle A Sahai; Hufeng Zhou; Jennifer Totonchy; David Jayabalan; Ruben Niesvizky; Ilaria Guasparri; Duane Hassane; Yifang Liu; Shizuko Sei; Robert H Shoemaker; J David Warren; Olivier Elemento; Kenneth M Kaye; Ethel Cesarman
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

7.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

Review 8.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

Review 9.  Phytotoxicity and Other Adverse Effects on the In Vitro Shoot Cultures Caused by Virus Elimination Treatments: Reasons and Solutions.

Authors:  Katalin Magyar-Tábori; Nóra Mendler-Drienyovszki; Alexandra Hanász; László Zsombik; Judit Dobránszki
Journal:  Plants (Basel)       Date:  2021-03-31

10.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.